Akari Therapeutics (AKTX) Other financing activities (2014 - 2025)

Akari Therapeutics (AKTX) posted quarterly Other financing activities of $1.0 million for Q4 2025, up 3803.7% year-on-year from $25616.7 in Q4 2024, and up 3233.33% on a QoQ basis from $30000.0 in Q2 2025.

Akari Therapeutics (AKTX) Other financing activities (2014 - 2025) Analysis & Trends

Akari Therapeutics (AKTX) has reported Other financing activities for 4 consecutive years, with $1.0 million the latest figure, recorded in Q4 2025.

  • Quarterly Other financing activities rose 3803.7% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 million (up 50050.0% YoY) and the FY2025 annual result came in at $1.0 million, up 51700.0% from the prior year.
  • Other financing activities advanced to $1.0 million in Q4 2025 per AKTX's latest filing, from $30000.0 in the prior quarter.
  • Over the last five years, Other financing activities for AKTX reached as high as $1.0 million in Q4 2025 and fell as low as -$27000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Akari Therapeutics 86.55 Mn 86.55 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 1.00 Mn
Dec 31, 2025 1.00 Mn
Jun 30, 2025 30,000.00
Jun 30, 2025 30,000.00
Dec 31, 2024 -27,000.00
Dec 31, 2024 -27,000.00
Sep 30, 2024 26,000.00
Sep 30, 2024 26,000.00
Mar 31, 2024 3,000.00
Mar 31, 2024 3,000.00
Jun 30, 2020 -2.76 Mn
Jun 30, 2020 -2.76 Mn
Mar 31, 2020 2.78 Mn
Mar 31, 2020 2.78 Mn
Mar 31, 2014 8.22 Mn
Mar 31, 2014 8.22 Mn